Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.61 |
| ▸ | MAOB | P27338 | 11/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CALML3 | P27482 | 1/20 | 0.48 |
| ▸ | SDHA | P31040 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969552 | 1.00 | MAOA (0.61) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11969284 | 0.91 | MAOA (0.63) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428880 | 0.89 | MAOA (0.76) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11968923 | 0.89 | MAOA (0.76) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11969173 | 0.88 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11969293 | 0.88 | MAOA (0.57) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428680 | 0.88 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428755 | 0.88 | MAOA (0.69) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11969025 | 0.88 | MAOA (0.69) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL11968843 | 0.88 | MAOA (0.80) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010036000-A2 | NOVEL OXAZOLIDINONE DERIVATIVES WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AND PHARMACEUTICAL COMPOSITIONS THEREOF | LEGOCHEM BIOSCIENCE LTD. (KR) | 2010-04-01 | — | — | WO | disclosed |